Clinical Trial Update: A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL [Phase 1, Phase 2]

View source ↗

Summary

The document provides a clinical trial update for a study evaluating subcutaneous blinatumomab in participants with relapsed/refractory and MRD-positive B-cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (Blincyto) (blinatumomab)

Snippet

Sponsor: Amgen | Conditions: B Cell Precursor Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: RECRUITING